DF

David Fuller

AdAlta Limited | Non-Executive Director
Mr Fuller has more than 30 years of experience in pre-clinical, clinical development, medical and regulatory affairs with specialisations in early phase development and oncology. He has led five product approvals in the United States (US) and European Union (EU) for orphan and major market products, together with multiple Regulatory Agency (US/EU) interactions including Investigational New Drug (IND) applications. David has designed and executed Phase I - III studies in US, EU and Asia across multiple therapeutic areas. David is currently Chief Medical Officer for Aucentra Therapeutics and is also Chair of EpiAxis Therapeutics Pty Ltd.

Company and Role

Company
Title
Tenure
Since
1AD
AdAlta Limited
  • Non-Executive Director
3yrs, 10mthJul 2020

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
1AD
AdAlta Limited
19/12/230294,9362,992,134N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
1AD
AdAlta Limited
19/12/23
Issued
1,750,000$0.013$22,092Issue of options
1AD
AdAlta Limited
29/05/23
Issued
84,268$0.025$2,106Rights issue
1AD
AdAlta Limited
29/05/23
Transfer
210,668$0.024$5,056Off-market transfer
1AD
AdAlta Limited
29/05/23
Transfer
210,668$0.024$5,056Off-market transfer
1AD
AdAlta Limited
29/05/23
Issued
42,134$0.024$1,011Rights issue